Aids

In HIV, progression of illness or treatment failure is often characterized by increased HIV viral load and decreased CD4+ T-cell count. When illness progression or treatment failure occurs on ART, it is often a result of drug-resistant HIV.

SAN FRANCISCO — During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV survivor, addressed conference attendees and discussed her experiences of living with HIV.

A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables for HIV prevention which included the need for prior authorization and funding issues.

Millions of children in Africa rely on funding from the United States for HIV care or testing — support that was threatened last month when President Donald J. Trump froze foreign aid spending after taking office.

A 90-day review of U.S. foreign aid spending ordered by President Donald J. Trump has halted global health programs, including the U.S. President’s Emergency Plan for AIDS Relief and the President’s Malaria Initiative.

Although there is still no HIV vaccine and no promising candidates in the pipeline, data published throughout 2024 show the significant impacts of prevention efforts and tools.

Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no other HIV vaccine trial ever had: a regimen that seemed to work.

A notable proportion of health care providers plan to reduce or stop providing HIV care over the next half decade, even as the need for such care is expected to rise, results from a quantitative national survey showed.

Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.